These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25380183)

  • 1. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma.
    Anforth RM; Carlos GR; Scolyer RA; Chou S; Fernandez-Peñas P
    Melanoma Res; 2015 Feb; 25(1):91-4. PubMed ID: 25380183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 3. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
    Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
    Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of cell-free circulating BRAF
    Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
    Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
    Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.
    Alfallouji Y; Spencer A; Calonje E; Perrett CM; Watchorn R; Borysiewicz C; Hodgkinson T; Wasan H; Bunker CB; Sidwell RU
    Clin Exp Dermatol; 2022 Oct; 47(10):1857-1858. PubMed ID: 35633107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the Molecular Genetics of Dermoscopic Naevus Patterns.
    Tan JM; Tom LN; Soyer HP; Stark MS
    Dermatology; 2019; 235(1):19-34. PubMed ID: 30332666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer.
    Meneguzzo A; Lazzarotto A; Alaibac M
    In Vivo; 2020; 34(1):441-445. PubMed ID: 31882511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
    Green JS; Norris DA; Wisell J
    Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
    Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
    Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
    Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
    Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.